Pacific Biosciences of California Inc. buy UBS Group AG
Start price
17.11.23
/
50%
€7.17
Target price
17.11.24
€9.20
Performance (%)
-75.89%
Price
24.05.24
€1.73
Summary
This prediction is currently active. The BUY prediction by UBS_Group_AG for Pacific Biosciences of California Inc. is performing very badly with a performance of -75.89%. This prediction currently runs until 17.11.24. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacific Biosciences of California Inc. | -7.404% | -7.404% |
iShares Core DAX® | -0.205% | 2.528% |
iShares Nasdaq 100 | 1.613% | 4.733% |
iShares Nikkei 225® | -0.740% | 0.396% |
iShares S&P 500 | 0.267% | 2.720% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€5.53
16.02.24
16.02.24
€11.13
16.02.25
16.02.25
-68.72%
24.05.24
24.05.24